365betÌåÓýÔÚÏßÊÀ½ç±­

Skip to main content
You have permission to edit this article.
Edit

Experimental drug cuts genetic heart disease risk factor by 94% in trial

CHICAGO � The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented at a major medical meeting on Sunday.

The drug, lepodisiran, reduced levels of lipoprotein(a), orLp(a), by an average of 93.9% versus placebo over six months after a single 400 milligram dose. There were 72 patients in the 400 mg arm of the study, while 69 received a placebo.



Tags



×

Stay Updated in Minutes

Sign up for our flagship newsletter covering all the local news to keep you informed.

Please enter a valid email.
Thank you for subscribing!

I'm not interested

Get up-to-the-minute news sent straight to your device.

Topics

News Alerts

Breaking News

Breaking News (FlagLive!)

Sign Up

Sign up with

Have an account? Log In

You're all set!

Thank you .

Your account has been registered, and you are now logged in.

Check your email for details.

OK

Log In

Admin login Subscribe
Need an account? Sign Up

Reset Password

Submitting this form below will send a message to your email with a link to change your password.

Forgot Password

An email message containing instructions on how to reset your password has been sent to the email address listed on your account.

Email me a log in link

Promotional Offers

No promotional rates found.

Purchase Gift Purchase Access

Secure & Encrypted

Sign in with
Who is this gift for?
Who is this gift from?
Delivery date
What's your billing location?
Subtotal:
Total:
How would you like to pay?

Secure transaction. Secure transaction. Cancel anytime.

You're all set!

Thank you.

Your gift purchase was successful! Your purchase was successful, and you are now logged in.

OK

An error occurred